With 0.21 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.21 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $10.815 whereas the lowest price it dropped to was $10.56. The 52-week range on MESO shows that it touched its highest point at $22.00 and its lowest point at $5.78 during that stretch. It currently has a 1-year price target of $26.47. Beta for the stock currently stands at 2.39.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MESO was down-trending over the past week, with a drop of -0.65%, but this was up by 1.23% over a month. Three-month performance dropped to -9.64% while six-month performance fell -41.61%. The stock lost -46.06% in the past year, while it has gained 55.91% so far this year. A look at the trailing 12-month EPS for MESO yields -0.93 with Next year EPS estimates of -0.34.
Float and Shares Shorts:
At present, 127.62 million MESO shares are outstanding with a float of 127.00 million shares on hand for trading. On 2025-06-13, short shares totaled 2.69 million, which was 212.0 higher than short shares on 1747267200. In addition to Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) as the firm’s Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director, Dr. Eric A. Rose M.D. serves as its Chief Medical Officer & Executive Director.
Institutional Ownership:
Through their ownership of 0.031059999 of MESO’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MESO since 10 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 2 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MESO analysts setting a high price target of 30.0 and a low target of 24.0, the average target price over the next 12 months is 27.0. Based on these targets, MESO could surge 180.9% to reach the target high and rise by 124.72% to reach the target low. Reaching the average price target will result in a growth of 152.81% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.5009 being high and -$0.55983 being low. For MESO, this leads to a yearly average estimate of -$0.523. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
